Literature DB >> 10618083

Performance of immunoblotting in diagnosis of visceral Leishmaniasis in human immunodeficiency virus-Leishmania sp.-coinfected patients.

G Santos-Gomes1, S Gomes-Pereira, L Campino, M D Araújo, P Abranches.   

Abstract

This study evaluated the performance of immunoblotting with Leishmania infantum soluble antigens for the diagnosis of visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and immunocompetent patients and assessed the humoral responses of patients coinfected with HIV and Leishmania. In this work, the results of the immunoblot analysis were compared to those of parasitological examination (Giemsa-stained smears and/or parasite isolation in Novy, Nicolle, and MacNeal medium from bone marrow) and indirect immunofluorescence and counterimmunoelectrophoresis techniques. Patients were considered to be infected if one or more of the comparison techniques gave a positive result. Immunoblotting was considered to be positive if at least one band was present. For 198 HIV-positive patients with a clinical suspicion of visceral leishmaniasis, immunoblot analysis had a sensitivity of 70.6%, a specificity of 73.2%, and an accuracy of 72.7%. For a separate group of 40 immunocompetent patients not infected with Leishmania, the immunoblot analysis was negative for all patients (100% specificity), and for a third group of 32 immunocompetent patients with confirmed visceral leishmaniasis, the immunoblot analysis was positive for all patients (100% sensitivity). Sera of coinfected patients recognized few bands and recognized bands at lower intensities compared with sera from immunocompetent patients. The most frequently detected band was 63 to 66 kDa (55.9%), with the difference being statistically significant compared to frequency of detection of the other bands. This study confirms that the humoral response in patients coinfected with HIV and Leishmania is much lower than that in immunocompetent patients and that the immunoblot method is a sensitive, noninvasive, and specific serological technique for the diagnosis of visceral leishmaniasis in immunocompromised patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10618083      PMCID: PMC86049          DOI: 10.1128/JCM.38.1.175-178.2000

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  19 in total

1.  An improved serodiagnostic procedure for visceral leishmaniasis.

Authors:  S G Reed; W G Shreffler; J M Burns; J M Scott; M da G Orge; H W Ghalib; M Siddig; R Badaro
Journal:  Am J Trop Med Hyg       Date:  1990-12       Impact factor: 2.345

2.  Indirect fluorescent immunoassay in the diagnosis of infantile and adult kala-azar.

Authors:  L Campino; P Abranches
Journal:  Trans R Soc Trop Med Hyg       Date:  1991 Jul-Aug       Impact factor: 2.184

Review 3.  How to read a paper. Papers that report diagnostic or screening tests.

Authors:  T Greenhalgh
Journal:  BMJ       Date:  1997-08-30

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  Evaluation of a newly developed direct agglutination test (DAT) for serodiagnosis and sero-epidemiological studies of visceral leishmaniasis: comparison with IFAT and ELISA.

Authors:  A E Harith; A H Kolk; P A Kager; J Leeuwenburg; F J Faber; R Muigai; S Kiugu; J J Laarman
Journal:  Trans R Soc Trop Med Hyg       Date:  1987       Impact factor: 2.184

6.  Evaluation of antibody responses in American visceral leishmaniasis by ELISA and immunoblot.

Authors:  T G Evans; E C Krug; M E Wilson; A W Vasconcelos; J E de Alencar; R D Pearson
Journal:  Mem Inst Oswaldo Cruz       Date:  1989 Apr-Jun       Impact factor: 2.743

7.  IgG antibody reactivity with Trypanosoma cruzi and Leishmania antigens in sera of patients with Chagas' disease and leishmaniasis.

Authors:  T M Chiller; M A Samudio; G Zoulek
Journal:  Am J Trop Med Hyg       Date:  1990-12       Impact factor: 2.345

8.  Use of purified parasite proteins from Leishmania donovani for the rapid serodiagnosis of visceral leishmaniasis.

Authors:  C L Jaffe; M Zalis
Journal:  J Infect Dis       Date:  1988-06       Impact factor: 5.226

9.  Western blot analysis of antibodies to Leishmania infantum antigens: potential of the 14-kD and 16-kD antigens for diagnosis and epidemiologic purposes.

Authors:  C Mary; D Lamouroux; S Dunan; M Quilici
Journal:  Am J Trop Med Hyg       Date:  1992-12       Impact factor: 2.345

10.  Antibody responses of visceral leishmaniasis patients to gp63, a major surface glycoprotein of Leishmania species.

Authors:  W G Shreffler; J M Burns; R Badaró; H W Ghalib; L L Button; W R McMaster; S G Reed
Journal:  J Infect Dis       Date:  1993-02       Impact factor: 5.226

View more
  14 in total

Review 1.  Diagnosis of visceral leishmaniasis.

Authors:  Pankaj Srivastava; Anand Dayama; Sanjana Mehrotra; Shyam Sundar
Journal:  Trans R Soc Trop Med Hyg       Date:  2010-11-11       Impact factor: 2.184

2.  Comparison of point-of-care tests for the rapid diagnosis of visceral leishmaniasis in East African patients.

Authors:  Asrat Bezuneh; Maowia Mukhtar; Asim Abdoun; Tedla Teferi; Yegnasew Takele; Ermias Diro; Asfaw Jemaneh; Welelta Shiferaw; Hirut Wondimu; Ajay Bhatia; Randall F Howard; Hashim Ghalib; Gregory C Ireton; Asrat Hailu; Steven G Reed
Journal:  Am J Trop Med Hyg       Date:  2014-10-13       Impact factor: 2.345

3.  Development of a Multiplexed Assay for Detection of Leishmania donovani and Leishmania infantum Protein Biomarkers in Urine Samples of Patients with Visceral Leishmaniasis.

Authors:  Claudia Abeijon; Fabiana Alves; Severine Monnerat; Monique Wasunna; Jane Mbui; Agostinho G Viana; Lilian L Bueno; Williane F Siqueira; Silvio G Carvalho; Neha Agrawal; Ricardo Fujiwara; Shyam Sundar; Antonio Campos-Neto
Journal:  J Clin Microbiol       Date:  2019-04-26       Impact factor: 5.948

4.  Identification and diagnostic utility of Leishmania infantum proteins found in urine samples from patients with visceral leishmaniasis.

Authors:  Claudia Abeijon; Suely S Kashino; Fernando O Silva; Dorcas L Costa; Ricardo T Fujiwara; Carlos H N Costa; Antonio Campos-Neto
Journal:  Clin Vaccine Immunol       Date:  2012-04-18

5.  Asymptomatic Leishmania infantum infection in an area of northwestern Italy (Piedmont region) where such infections are traditionally nonendemic.

Authors:  Alberto Biglino; Cesare Bolla; Erika Concialdi; Anna Trisciuoglio; Angelo Romano; Ezio Ferroglio
Journal:  J Clin Microbiol       Date:  2009-11-18       Impact factor: 5.948

6.  Novel Antigen Detection Assay to Monitor Therapeutic Efficacy of Visceral Leishmaniasis.

Authors:  Claudia Abeijon; Om Prakash Singh; Jaya Chakravarty; Shyam Sundar; Antonio Campos-Neto
Journal:  Am J Trop Med Hyg       Date:  2016-08-01       Impact factor: 2.345

Review 7.  The diagnostic accuracy of serologic and molecular methods for detecting visceral leishmaniasis in HIV infected patients: meta-analysis.

Authors:  Gláucia Fernandes Cota; Marcos Roberto de Sousa; Fábio Nogueira Demarqui; Ana Rabello
Journal:  PLoS Negl Trop Dis       Date:  2012-05-29

8.  Use of VHH antibodies for the development of antigen detection test for visceral leishmaniasis.

Authors:  Claudia Abeijon; Julia Dilo; Jacqueline M Tremblay; Agostinho G Viana; Lilian L Bueno; Silvio F G Carvalho; Ricardo T Fujiwara; Charles B Shoemaker; Antonio Campos-Neto
Journal:  Parasite Immunol       Date:  2018-09-11       Impact factor: 2.280

9.  Western Blot Analysis of Leishmania infantum Antigens in Sera of Patients with Visceral Leishmaniasis.

Authors:  Soudabeh Heidari; Javad Gharechahi; Mehdi Mohebali; Behnaz Akhoundi; Shahab Mirshahvaladi; Bahareh Azarian; Homa Hajjaran
Journal:  Iran J Parasitol       Date:  2019 Jan-Mar       Impact factor: 1.012

Review 10.  Potential non-invasive urine-based antigen (protein) detection assay to diagnose active visceral leishmaniasis.

Authors:  Claudia Abeijon; Antonio Campos-Neto
Journal:  PLoS Negl Trop Dis       Date:  2013-05-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.